The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Open accessAbstract
Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated beverages and a reduced risk of developing Parkinson's disease (PD). To explore the possibility that caffeine helps prevent the dopaminergic deficits characteristic of PD, we investigated the effects of caffeine and the adenosine receptor subtypes through which it may act in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD. Caffeine, at doses comparable to those of typical human exposure, attenuated MPTP-induced loss of striatal dopamine and dopamine transporter binding sites. The effects of caffeine were mimicked by several A(2A) antagonists (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261), 3,7-dimethyl-1-propargylxanthine, and (E)-1,3-diethyl-8 (KW-6002)-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione) (KW-6002) and by genetic inactivation of the A(2A) receptor, but not by A(1) receptor blockade with 8-cyclopentyl-1,3-dipropylxanthine, suggesting that caffeine attenuates MPTP toxicity by A(2A) receptor blockade. These data establish a potential neural basis for the inverse association of caffeine with the development of PD, and they enhance the potential of A(2A) antagonists as a novel treatment for this neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
A2AAdenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice
Chen, J.-F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M. A., Fink, J. S., & Schwarzschild, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09192.1999 · Cited by 557
Self-citationDistribution, biochemistry and function of striatal adenosine A2A receptors
Svenningsson, P. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00011-8 · Cited by 516
Schauwecker, P. E., & Steward, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4103 · Cited by 506
Gerlach, M., & Riederer, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 498
Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain
Siegel, G. J., & Chauhan, N. B. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00030-8 · Cited by 496
Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K. B., Nakamura, J., Kase, H., Kuwana, Y., & Jenner, P. (1998) · Annals of Neurology · doi:10.1002/ana.410430415 · Cited by 354
Cited by
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Metadata
- Authors
- Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2001-05-15
- Volume
- 21
- Issue
- 10
- Pages
- RC143-RC143
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2141364712
- Cited by
- 606
- References
- 27
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease. https://app.cochat.ai/papers/10.1523/jneurosci.21-10-j0001.2001
- The paper
- Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001). Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.21-10-j0001.2001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
